Cardiovascular Safety in Patients Receiving Roflumilast for the Treatment of COPD

References

Page 1

	Year	Citations
Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease Peter Calverley, Julie A. Anderson, Bartolomé R. Celli, New England Journal of Medicine	2007	3.2K
Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. GOLD executive summary Klaus F. Rabe American Journal of Respiratory and Critical Care Medicine Chronic Disease ManagementHealth PolicyAdvanced Lung DiseaseGold Executive SummaryGlobal Health	2007	2.6K
A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary Disease Donald P. Tashkin, Bartolomé R. Celli, Stephen Senn, New England Journal of Medicine	2008	2.2K
Why Are Patients With Chronic Obstructive Pulmonary Disease at Increased Risk of Cardiovascular Diseases? Don D. Sin, S. F. Paul Man Circulation	2003	1.1K
Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials Peter M.A. Calverley, Klaus F. Rabe, Udo-Michael Goehring, The Lancet Antifibrotic TherapyPulmonary CareClinical TrialsPulmonary MedicineMedicine	2009	808
From COPD to chronic systemic inflammatory syndrome? Leonardo M. Fabbri, Klaus F. Rabe The Lancet InflammationChronic DiseaseSystemic Inflammatory SyndromeMedicinePulmonary Disease	2007	618
Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials Leonardo M. Fabbri, Peter M.A. Calverley, José Luís Izquierdo Alonso, The Lancet Longacting BronchodilatorsAdvanced Lung DiseaseClinical TrialsPulmonary PharmacologyPulmonary Medicine	2009	604
COPD and Incident Cardiovascular Disease Hospitalizations and Mortality: Kaiser Permanente Medical Care Program Stephen Sidney, Michael Sorel, Charles P. Quesenberry, CHEST Journal Pulmonary CareCardiovascular DiseasePulmonary MedicineMedicinePulmonary Disease	2005	530
Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease. Annemie Schols, Wim A. Buurman, A. J. Staal van den Brekel, Thorax	1996	523
Roflumilast—an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial Klaus F. Rabe, Eric Bateman, Denis O’Donnell, The Lancet AsthmaInflammationAntifibrotic TherapyAnti-inflammatoryInflammatory Lung Disease	2005	466

Page 1